Day: October 14, 2023

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab (UX143) significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD). The data were presented in a late-breaker...

Virginia Congressional and State Officials join bakery employees in honoring home of Oreo, Chips Ahoy!, Nilla Wafers, Ritz, Wheat Thins and more leading snacking brandsRICHMOND, Va., Oct. 14, 2023 (GLOBE NEWSWIRE) — Mondelēz International, Inc. (Nasdaq: MDLZ) today marked the 50th anniversary of its beloved Richmond Biscuit Manufacturing Plant with a recognition ceremony and family-friendly celebration. Federal, state and local elected officials, honored guests and company leadership enjoyed the anniversary festivities alongside generations of local employees and their families. Since operations began in 1973, the Richmond Bakery has played a key role in supporting U.S. biscuit manufacturing for Mondelēz International, making and baking a range of consumer favorite cookies and crackers, including Oreo, Chips Ahoy!, Nilla Wafers,...

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – – IND and initiation of clinical trial planned in 2H 2024 – WALTHAM, Mass. and BOULDER, Colo., Oct. 14, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, announced updated preclinical data from the Company’s next-generation selective fibroblast growth factor receptor 2 (FGFR2) program being presented today in a poster presentation at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston. “We are excited to share these new data on our internally discovered and developed...

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 – 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude’s CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for our SMARCA2 degrader compound, PRT3789. “This additional data from our solid tumor trial investigating our potent and selective CDK9 inhibitor, PRT2527, continues to support a best-in-class safety and target engagement profile...

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three active once daily doses of 100mg, 200mg and 300mg Initial NSCLC expansion cohort data expected in 2024 Initial GBM dose escalation data expected later this year CAMBRIDGE, Mass. and NEW YORK, Oct. 14, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today presented results demonstrating encouraging response durability of BDTX-1535 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). BDTX-1535, a fourth-generation, brain-penetrant...

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemotherapy — — Toripalimab demonstrated twelve-fold higher binding affinity to PD-1 compared to pembrolizumab — — In vitro studies show significantly higher activation of T cells compared to pembrolizumab in multiple assay systems — REDWOOD CITY, Calif., Oct. 14, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced a presentation of toripalimab data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 11-15, 2023 at the Hynes Convention Center in Boston. PD-L1, a protein found on the surface of some cancer cells, suppresses T cell activation...

Vancouver, B.C, Oct. 14, 2023 (GLOBE NEWSWIRE) — Keon Capital Inc. (“Keon” or the “Company”) (TSXV: KEON.H) announces that Mr. Harry Nijjar has been appointed as Chief Financial Officer and Corporate Secretary of the Company, effective immediately. Mr. Nijjar is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. As CFO of Keon Mr. Nijjar will be responsible for the financial reporting and other administrative functions. Mr. Nijjar replaces Mr. Luke Montaine, who has resigned as a director, CFO and Corporate Secretary of the Company to focus on other endeavors. The board of directors of Keon thank Mr. Montaine for his contributions to the Company. On behalf of the Board of Directors “Nader Vatanchi” Chief Executive OfficerTel:...

TORONTO, Oct. 13, 2023 (GLOBE NEWSWIRE) — POET Technologies Inc. (the “Company” or “POET”) (TSXV: PTK; NASDAQ: POET) hereby reports on the sales under the Company’s “at-the-market” equity program (the “ATM Program”) during the fiscal quarter ended September 30, 2023. The ATM Program was initially active in both the United States and Canada pursuant to an equity distribution agreement dated June 29, 2023 among the Company, Craig-Hallum Capital Group LLC (“Craig-Hallum”) and Cormark Securities Inc. (“Cormark”) and conducted under a prospectus supplement dated June 29, 2023 to the Company’s short form base shelf prospectus dated June 30, 2021 and U.S. registration statement on Form F-10, which included the base shelf prospectus. Following the expiry of the Company’s...